TY - JOUR
T1 - Host immune response–inspired development of the influenza vaccine
AU - Choi, Angela
AU - García-Sastre, Adolfo
AU - Schotsaert, Michael
N1 - Funding Information:
Funding Sources: Influenza immunogenicity studies in the AG-S lab are also supported by grants U19AI117873, U01AI124297, R01AI127658, R01AI127775, P01AI097092, U19AI135972, R01AI141226, and U19AI142733 from the National Institute of Allergy and Infectious Disease ( NIAID ); grant U01 EB029085 from the National Institute of Biomedical Imaging and Bioengineering; grant W81XWH-18-1-0488 from the US Department of Disease, the Bill and Melinda Gates Foundation , the Center for Research on Influenza Pathogenesis; contract HHSN272201400008C with the NIAID-funded Center of Excellence on Influenza Research and Surveillance; and contract 75N93019C00051 with the NIAID-funded Collaborative Influenza Vaccine Innovation Center.
Funding Information:
Disclosures: Adolfo Garc?a-Sastre is an inventor of patents owned by the Icahn School of Medicine at Mount Sinai in the field of influenza virus vaccines. The AG-S laboratory has received research funds from Avimex, GSK, and 7Hills to investigate novel influenza virus vaccines.Funding Sources: Influenza immunogenicity studies in the AG-S lab are also supported by grants U19AI117873, U01AI124297, R01AI127658, R01AI127775, P01AI097092, U19AI135972, R01AI141226, and U19AI142733 from the National Institute of Allergy and Infectious Disease (NIAID); grant U01 EB029085 from the National Institute of Biomedical Imaging and Bioengineering; grant W81XWH-18-1-0488 from the US Department of Disease, the Bill and Melinda Gates Foundation, the Center for Research on Influenza Pathogenesis; contract HHSN272201400008C with the NIAID-funded Center of Excellence on Influenza Research and Surveillance; and contract 75N93019C00051 with the NIAID-funded Collaborative Influenza Vaccine Innovation Center.
Publisher Copyright:
© 2020 The Authors
PY - 2020/7
Y1 - 2020/7
N2 - Objective: To assess the current and future development of influenza vaccines. Data Sources: PubMed searches were performed cross-referencing the keywords influenza, influenza vaccine, host immune response, correlates of protection, vaccine development, vaccine efficacy. Articles were reviewed for additional citations. Study Selections: Articles were reviewed and selected on the basis of relevance to subject matter. Results: In this review, we first introduce the influenza virus, its nomenclature, and the concepts of antigenic drift and shift. Second, we discuss the status of currently licensed influenza virus vaccines. We briefly focus on influenza vaccine responses beyond hemagglutination inhibition that may correlate with protection against influenza viruses of different subtypes. Third, we explain how studying host responses to influenza infection and vaccination with advanced serologic methods, B-cell receptor sequencing, and transcriptomic profiling can guide the development of improved influenza virus vaccines. Fourth, we provide 2 suggestions on how current influenza vaccines can be optimized by redirecting immune responses toward conserved viral antigens and the use of adjuvants. Conclusion: Influenza vaccine design can benefit from novel insights obtained from the study of host responses to influenza virus infection and vaccination. Integration of the large amount of available clinical and preclinical data requires systems approaches that can elucidate novel correlates of protection and will guide further development of influenza vaccine.
AB - Objective: To assess the current and future development of influenza vaccines. Data Sources: PubMed searches were performed cross-referencing the keywords influenza, influenza vaccine, host immune response, correlates of protection, vaccine development, vaccine efficacy. Articles were reviewed for additional citations. Study Selections: Articles were reviewed and selected on the basis of relevance to subject matter. Results: In this review, we first introduce the influenza virus, its nomenclature, and the concepts of antigenic drift and shift. Second, we discuss the status of currently licensed influenza virus vaccines. We briefly focus on influenza vaccine responses beyond hemagglutination inhibition that may correlate with protection against influenza viruses of different subtypes. Third, we explain how studying host responses to influenza infection and vaccination with advanced serologic methods, B-cell receptor sequencing, and transcriptomic profiling can guide the development of improved influenza virus vaccines. Fourth, we provide 2 suggestions on how current influenza vaccines can be optimized by redirecting immune responses toward conserved viral antigens and the use of adjuvants. Conclusion: Influenza vaccine design can benefit from novel insights obtained from the study of host responses to influenza virus infection and vaccination. Integration of the large amount of available clinical and preclinical data requires systems approaches that can elucidate novel correlates of protection and will guide further development of influenza vaccine.
UR - http://www.scopus.com/inward/record.url?scp=85084527670&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2020.04.008
DO - 10.1016/j.anai.2020.04.008
M3 - Review article
C2 - 32325117
AN - SCOPUS:85084527670
SN - 1081-1206
VL - 125
SP - 28
EP - 35
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 1
ER -